Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

The conversation discusses the use of pyrilutamide as an adjunct treatment for hair loss, particularly for those already using finasteride and minoxidil. Users share mixed experiences, with some reporting side effects like numbness and gynecomastia, while others note its potential benefits in reducing shedding and scalp itchiness.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Copper peptides are being discussed for hair loss treatment, with users reporting positive results using topical applications. There is interest in sourcing, application methods, and potential side effects.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

The conversation is about a user who had a hair transplant with 2,850 grafts and switched from finasteride and topical minoxidil to oral minoxidil and dutasteride for better results. They are hopeful for full results in a year.

The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

The conversation discusses hair transplant options, comparing the US and Turkey, with suggestions to consider Mexico, Thailand, and other countries. It emphasizes starting treatments like finasteride, minoxidil, and microneedling before proceeding with a transplant.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

PP405 is being discussed as a promising hair loss treatment, potentially effective when combined with minoxidil and pyrilutamide. Some users are skeptical about rapid hair regrowth claims, while others are considering alternatives like GT20029 and pyrilutamide instead of finasteride.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

The user shared progress on hair regrowth after a third verteporfin procedure, using oral dutasteride, extended-release oral minoxidil, and occasional microneedling. The results were positively received by others.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.